Comparison of traditional and next-generation oral anticoagulants in the etiology of epistaxis
Traditional and novel anticoagulants in epistaxis
Keywords:
Epistaxis, Anticoagulants, Warfarin, Rivaroxaban, DabigatranAbstract
Background/Aim: There is a dearth of studies addressing the effects of next-generation anticoagulants on epistaxis. The aim of this investigation was to determine whether there are any differences between traditional and next-generation anticoagulants in the etiology of epistaxis.
Methods: This retrospective cohort study focused on a total of 7,110 individuals (3,278 females (46.1%) and 3,832 males (53.9%)) diagnosed with epistaxis between 2018 and 2022; the mean age of the patients was 37.7 years. Patient data (age, gender, outpatient and inpatient treatments, relevant laboratory parameters, and treatment evidence) were retrospectively reviewed from a hospital database. The severity of epistaxis was assessed based on treatment notes. Patients with hypertension and those undergoing antiaggregant therapy were excluded from the study. International Classification of Diseases (ICD) codes from the automated system were examined retrospectively. The data were used to establish three patient groups: the first group consisted of individuals taking next-generation oral anticoagulants, the second group consisted of individuals taking traditional oral anticoagulants, and the third group consisted of healthy controls.
Results: We found statistically significant differences among the groups in terms of age, the severity of epistaxis, the treatment modality, and laboratory findings (P<0.001); no statistically significant difference was found in terms of gender (P=0.954). Group 2 contained the largest number of hospitalized patients and patients with severe active nosebleeds.
Conclusion: Next-generation anticoagulants are more reliable than traditional anticoagulants in terms of the severity of epistaxis, the need for hospitalization, and laboratory results.
Downloads
References
Cohen O, Shoffel-Havakuk H, Warman M, Tzelnick S, Haimovich Y, Kohlberg GD, et al. Early and Late Recurrent Epistaxis Admissions: Patterns of Incidence and Risk Factors. Otolaryngol Head Neck Surg. 2017;157:424-31. DOI: https://doi.org/10.1177/0194599817705619
Krulewitz NA, Fix ML. Epistaxis. Emerg Med Clin North Am. 2019;37:29-39. DOI: https://doi.org/10.1016/j.emc.2018.09.005
Neshewat J, Wasserman A, Alexandris-Souphis C, Haymart B, Feldeisen D, Kong X, et al. Reduction in epistaxis and emergency department visits in patients taking warfarin after implementation of an education program. Thromb Res. 2021;199:119-22. DOI: https://doi.org/10.1016/j.thromres.2021.01.007
Douglas R, Wormald PJ. Update on epistaxis. Curr Opin Otolaryngol Head Neck Surg. 2007;15:180-3. DOI: https://doi.org/10.1097/MOO.0b013e32814b06ed
Sowerby LJ, DeSerres JJ, Rudmik L, Wright ED. Role of season, temperature and humidity on the incidence of epistaxis in Alberta, Canada. J Otolaryngol Head Neck Surg. 2014;43:10. DOI: https://doi.org/10.1186/1916-0216-43-10
Tunkel DE, Anne S, Payne SC, Ishman SL, Rosenfeld RM, Abramson PJ, et al. Clinical Practice Guideline: Nosebleed (Epistaxis). Otolaryngol Head Neck Surg. 2020;162:1-38. DOI: https://doi.org/10.1177/0194599819890327
Chaaban MR, Zhang D, Resto V, Goodwin JS. Demographic, seasonal, and geographic differences in emergency department visits for epistaxis. Otolaryngol Head Neck Surg. 2017;156:81-6. DOI: https://doi.org/10.1177/0194599816667295
Purkey MR, Seeskin Z, Chandra R. Seasonal variation and predictors of epistaxis. Laryngoscope. 2014;124:2028–33. DOI: https://doi.org/10.1002/lary.24679
Riviello RJ. Otolaryngologic procedures. In: Clinical Procedures in Emergency Medicine, 4th, Roberts JR, Hedges JR (Eds), WB Saunders, Philadelphia, 2004; p.1300
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. DOI: https://doi.org/10.1056/NEJMoa1009638
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. DOI: https://doi.org/10.1056/NEJMoa0905561
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. DOI: https://doi.org/10.1056/NEJMoa1107039
Pallin DJ, Chng YM, McKay MP, Emond JA, Pelletier AJ, Camargo CA Jr. Epidemiology of epistaxis in US emergency departments, 1992 to 2001. Ann Emerg Med. 2005;46:77-81. DOI: https://doi.org/10.1016/j.annemergmed.2004.12.014
Viehweg TL, Roberson JB, Hudson JW. Epistaxis: diagnosis and treatment. J Oral Maxillofac Surg. 2006;64:511-8. DOI: https://doi.org/10.1016/j.joms.2005.11.031
Seidel DU, Sesterhenn AM, Kostev K. Seasonal Variation of Epistaxis in Germany. J Craniofac Surg. 2018;29:365-7. DOI: https://doi.org/10.1097/SCS.0000000000004351
Huang CL, Shu CH. Epistaxis: a review of hospitalized patients. Zonghua Yi Xue Za Zhi (Taipei). 2002;65:74-8.
Bermüller C, Bender M, Brögger C, Petereit F, Schulz M. Epistaxis and anticoagulation - a medical and economic challenge? Laryngorhinootologie. 2014;93:249-55. DOI: https://doi.org/10.1055/s-0033-1355400
Andreotti F, Rocca B, Husted S, Ajjan RA, ten Berg J, Cattaneo M, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2015;36:3238–49. DOI: https://doi.org/10.1093/eurheartj/ehv304
Ho JPK, Bari N, Riffat F. Management of epistaxis in patients on novel oral anticoagulation therapy. J Laryngol Otol. 2020;134:316-22. DOI: https://doi.org/10.1017/S0022215120000754
Buchberger AMS, Baumann A, Johnson F, Peters N, Piontek G, Storck K, et al. The role of oral anticoagulants in epistaxis. Eur Arch Otorhinolaryngol. 2018;275:2035-43. DOI: https://doi.org/10.1007/s00405-018-5043-z
Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74–81. DOI: https://doi.org/10.1124/dmd.108.023143
Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest. 2012;141:120–51. DOI: https://doi.org/10.1378/chest.11-2294
Suzuki S, Otsuka T, Sagara K, Semba H, Kano H, Matsuno S, et al. Nine-year trend of anticoagulation use, thromboembolic events, and major bleeding in patients with non-valvular atrial fibrillation- shinken database analysis. Circ J. 2016;80:639–49. DOI: https://doi.org/10.1253/circj.CJ-15-1237
Rubboli A, Becattini C, Verheugt FW. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol. 2011:3:351–8. DOI: https://doi.org/10.4330/wjc.v3.i11.351
Gomes P, Salvador P, Lombo C, Caselhos S, Fonseca R. Role of age and anticoagulants in recurrent idiopathic epistaxis. Acta Otorrinolaringol Esp. 2020;71:160-5. DOI: https://doi.org/10.1016/j.otorri.2019.05.003
L’Huillier V, Badet C, Tavernier L. Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants. Eur Ann Otorhinolaryngol Head Neck Dis 2018;135:231–5. DOI: https://doi.org/10.1016/j.anorl.2018.04.006
Sauter TC, Hegazy K, Hautz WE, Krummrey G, Ricklin ME, Nagler M, et al. Epistaxis in anticoagulated patients: fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. Clin Otolaryngol. 2018;43:103–8. DOI: https://doi.org/10.1111/coa.12904
Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, et al. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2016;116:544–53. DOI: https://doi.org/10.1160/TH15-12-1000
Gökdogan O, Akyildiz I, Sayin BY, Okutucu S, Tanalp AC, Arslan N. The rate of epistaxis incidence in new generation anticoagulants and perioperative approach in otorhinolaryngological practices. J Craniofac Surg. 2017;28:178–82. DOI: https://doi.org/10.1097/SCS.0000000000003135
Send T, Bertlich M, Horlbeck F, Schafigh D, Freytag S, Eichhorn KW, et al. Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin. Int Forum Allergy Rhinol. 2019;9:120–4. DOI: https://doi.org/10.1002/alr.22210
Yaniv D, Zavdy O, Sapir E, Levi L, Soudry E. The impact of traditional anticoagulants, novel antikoagulants and antiplatelets on epistaxis. Laryngoscope. 2021;131:1946-51. DOI: https://doi.org/10.1002/lary.29417
Spielmann P, Barnes M, White P. Controversies in the specialist management of adult epistaxis: an evidence-based review. Clin Otolaryngol. 2012;37:382–9. DOI: https://doi.org/10.1111/coa.12024
Sandoval C, Dong S, Visintainer P, Ozkaynak MF, Jayabose S. Clinical and laboratory features of 178 children with recurrent epistaxis. J Pediatr Hematol Oncol. 2002;24:47–9. DOI: https://doi.org/10.1097/00043426-200201000-00013
Thaha M, Nilssen E, Holland S, Love G, White PS. Routine coagulation screening in the management of emergency admission for epistaxis – is it necessary? J Laryngol Otol. 2000;114:38–40. DOI: https://doi.org/10.1258/0022215001903861
Béquignon E, Teissier N, Gauthier A, Brugel L, De Kermadec H, Coste A, et al. Emergency department care of childhood epistaxis. Emerg Med J. 2017;34:543–8. DOI: https://doi.org/10.1136/emermed-2015-205528
Horton JD, Bushwick B. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999;59:635–46.
Downloads
- 76 95
Published
Issue
Section
How to Cite
License
Copyright (c) 2024 Süheyla Kandemir, Hüseyin Kandemir
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.